

RECEIVED  
CENTRAL FAX CENTER  
AUG 16 2006**Replacement Response to Requirement for Restriction**

In response to the species election imposed by the Examiner, Applicants elect examination of claims directed to the use of the indicated compounds for the treatment/prevention of "neoplastic disease." Applicants reserve the right to retain the non-elected species in the current claims as discussed in MPEP 809.02(e), 809.03 and, particularly, 809.04.

Pursuant to the restriction requirement claims 9-13, and 20-25 have been withdrawn. Additionally, claims 1, 14, 26 and 29 have been amended and new claims 31-84 have been added. Support for the foregoing claims amendments and new claims can be found as indicted below.

Claims 1 and 26, see Fig 2A and 2B regarding the "R<sup>1</sup>" groups. Also see Fig. 1 and the structural formulas for compounds 14 (pg. 40), 16 (pg. 43), 17 (pg. 44), 23 (pg. 65), 24 (pg. 67), 25 (pg. 68), 26 (pg. 68), 28 (pg. 72) and 29 (pg. 74) regarding the "R<sup>5</sup>" groups.


Claims 14 and 29, the new compounds added to the claim are compounds 20 (pg. 56) and 22 (pg. 60).

Claims 31-84, support can be found as indicted for amended claims 1 and 25.

**Conclusion**

This is submitted to be a complete response to the referenced Requirement for Restriction. The Examiner is invited to contact the undersigned at (512) 536-3055 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

  
David L. Parker  
Reg. No. 32,165  
Attorney for Applicants

FULBRIGHT & JAWORSKI, L.L.P.  
600 Congress Ave., Ste. 1900  
Austin, Texas 78701  
(512) 536-3055  
(512) 536-4598 (facsimile)

Date: August 16, 2006